Osimertinib Resistance and EGFR Mutations in NSCLC Treatment
Bioengineer
JANUARY 16, 2024
Analysis of circulating tumor (ct) DNA at the time of treatment discontinuation or progression showed that 49% of patients in the AURA3 trial lacked the T790M mutation. Analysis of circulating tumor (ct) DNA at the time of treatment discontinuation or progression showed that 49% of patients in the AURA3 trial lacked the T790M mutation.
119 
Let's personalize your content